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Sapovirus (SaV) is a causative agent of gastroenteritis. 
On the basis of capsid protein (VP1) nucleotide sequences, 
SaV can be divided into 5 genogroups (GI–GV), of which 
the GI, GII, GIV, and GV strains infect humans. SaV is un-
cultivable, but expression of recombinant VP1 in insect cells 
results in formation of viruslike particles (VLPs) that are 
antigenically similar to native SaV. In this study, we newly 
expressed SaV GII and GIV VLPs to compare genetic and 
antigenic relationships among all human SaV genogroups. 
Hyperimmune antiserum samples against VLPs reacted 
strongly with homologous VLPs. However, several antise-
rum samples weakly cross-reacted against heterologous 
VLPs in an antibody ELISA. Conversely, an antigen ELISA 
showed that VLPs of SaV in all human genogroups were 
antigenically distinct. These ﬁ  ndings indicate a likely corre-
spondence between SaV antigenicity and VP1 genogroup-
ing and genotyping.
T
he family Caliciviridae contains 4 genera (Sapovirus, 
Norovirus, Lagovirus, and Vesivirus), which include 
Sapporo virus, Norwalk virus, Rabbit hemorrhagic disease 
virus, and Feline calicivirus, respectively. Sapoviruses 
(SaVs) and noroviruses (NoVs) are etiologic agents of hu-
man gastroenteritis. The prototype strain of human SaV, 
Sapporo virus, was originally discovered in an outbreak in 
an orphanage in Sapporo, Japan, in 1977 (1). SaV infects 
children and adults and has been found to cause outbreaks 
of gastroenteritis in daycare centers, healthcare facilities, 
and elementary schools. Detection methods include reverse 
transcription–PCR (RT-PCR), real-time RT-PCR, enzyme 
immunoassays, and ELISAs (2–6). Recently, we detected 
SaV in untreated wastewater samples, treated wastewater 
samples, and river samples (7).
The SaV genomes are predicted to contain either 2 or 3 
main open reading frames (ORF1–3). SaV ORF1 encodes 
for nonstructural proteins and the major capsid protein, and 
ORF2 (VP2) and ORF3 encode proteins of yet unknown 
functions. On the basis of VP1 nucleotide sequences, SaVs 
have been divided into 5 genogroups (GI–GV), of which 
GI, GII, GIV, and GV strains infect humans and GIII strains 
infect porcine species (8). SaV genogroups can be further 
subdivided into genotypes. Recently, we identiﬁ  ed several 
recombinant SaV strains (8,9).
Human SaV and NoV strains are uncultivable, but 
expression of a recombinant subgenomic-like construct 
(i.e., VP1 to the end of the genome) or VP1 alone in insect 
or mammalian cells results in the formation of viruslike 
particles (VLPs) that are morphologically similar to na-
tive SaV (10–16). However, production of VLPs of SaV 
remains difﬁ  cult, usually only resulting in low yields of 
VLPs compared with norovirus (10,12,16,17). Cryoelec-
tron microscopy and x-ray crystallography analyses of 
NoV VLPs identiﬁ  ed the shell (S) and protruding domains 
(subdomains P1–1, P1–2, and P2) (18). Also, Chen et al. 
described strictly and moderately conserved amino acid 
residues in the capsid protein among the 4 genera in the 
family Caliciviridae (13).
Previously, we reported that SaV GI/1 (strain Mc114) 
and GV/1 (strain NK24) were antigenically distinct (5,10). 
More recently, we discovered that SaV GI/5 (strain Yo-
kote1) VLPs were antigenically distinct from SaV GI/1 
Mc114 and GV/1 NK24 VLPs (19). Other than these few 
studies, little is known about the genetic and antigenic re-
lationships among the 4 human SaV genogroups. For clas-
siﬁ  cation of NoV, distinct genotypes have been deﬁ  ned as 
having bootstrap values >950 (VP1 sequences); at least 
14 GI and 17 GII genotypes have been identiﬁ  ed (20). For 
SaV, genogroups have only been vaguely deﬁ  ned, mostly 
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because 2 of them (GIV/1 and GV/1) were only recently 
identiﬁ  ed, few sequences exist in the database, and antigen-
ic relationships among all genogroups are unknown. In ad-
dition, genetic recombination was only recently discovered 
and appears to be common within the genus Sapovirus. 
The purpose of this study was to examine cross-reac-
tivities among the 4 human SaV genogroups and compare 
results with those of genetic analysis. For this purpose, 2 
other SaV strains, GII/3 Syd53 and GIV/1 Syd3, were ex-
pressed and antisera were produced against their puriﬁ  ed 
VLPs. A total of 5 SaV strains (GI/1 Mc114, GI/5 Yokote1, 
GII/3 Syd53, GIV/1 Syd3, and GV/1 NK24) that include all 
4 human genogroups and 2 GI genotypes were compared. 
Our results show that SaV genogroups were antigenically 
distinct and corresponded with results of genetic classiﬁ  ca-
tion on the basis of full-length VP1 nucleotide sequences. 
Proper genetic classiﬁ  cation of SaV strains is required, and 
a consensus of genogroups and genotypes that represent 
genetically and antigenically diverse strains, which include 
recombinant SaV strains, should be established to avoid 
conﬂ  icting grouping.
Materials and Methods
Specimens
Virus-positive stool specimens were collected from 
several sources. SaV strain Mc114 (GenBank accession 
no. AY237422) was isolated from an infant hospitalized 
with acute gastroenteritis in Chiang Mai, Thailand, in 2001 
(21). SaV strain NK24 (AY646856) was isolated from an 
infant with gastroenteritis in Nong Khai, Thailand, in 2003 
(22). SaV strain Yokote1 was isolated from an outbreak 
of gastroenteritis at a kindergarten in Yokote City, Japan, 
in 2006 (19). SaV strains Syd53 and Syd3 were isolated 
from infants hospitalized with acute gastroenteritis in Syd-
ney, New South Wales, Australia, in 2001 (23). NoV strain 
Osaka659 was isolated from an outbreak of gastroenteritis 
in Japan, in 2006 (unpub. data). RNA extraction and RT-
PCR were performed as described (24).
Sequence Analysis
Nucleotide sequences were determined by using the 
Terminator Cycle Sequence Kit version 3.1 and an ABI 
3130 sequencer (both from Applied Biosytems, Boston, 
MA, USA). Nucleotide sequences were aligned with Clust-
alX (www.embl.de/∼chenna/clustal/darwin) and the dis-
tances were calculated by the Kimura 2-parameter method 
(24). Phylogenetic trees with bootstrap analysis from 1,000 
replicas were generated by the neighbor-joining method as 
described (20). Amino acid VP1 secondary structure pre-
dictions were made by using PSIPRED secondary struc-
tural prediction software (25).
Expression of Viruslike Particles
For the expression of VP1 in insect cells, all SaV con-
structs were designed to begin from the predicted VP1 start 
AUG codon and included the ORF2 and poly(A) sequenc-
es. SaV strains Syd53 and Syd3 were cloned as described 
(10) for strains SaV Mc114, NK24, and Yokote1 according 
to the protocol of the Baculovirus Expression System using 
Gateway Technology (Invitrogen, Carlsbad, CA, USA). 
Brieﬂ  y, strains Syd53 and Syd3 were ampliﬁ  ed with specif-
ic sense primers Syd53attb1 (5′-GGGGACAAGTTTGTA
CAAAAAAGCAGGCTTCGAAGGAGATAGAACCAT
GGAGGGTGTGTCCCACCCAGA-3′) and Syd3attb1 (5′-G
GGGACAAGTTTGTACAAAAAAGCAGG
CTTCGAAGGAGATAGAACCATGGAGGGCAATGG
CCTACCCCAGGCTG-3′) and antisense primer TX30SXN 
(5′-GACTAGTTCTAGATCGCGAGCGGCCGCCCT
TTTTTTTTTTTTTTTTTTTTTTTTTTTTT-3′). PCR frag-
ments were puriﬁ  ed after electrophoresis on a 1.0% agarose 
gel. Fragments were cloned into donor vector pDONR201 
(Invitrogen) and transferred into a baculovirus transfer vec-
tor pDEST8 (Invitrogen). 
The recombinant pDEST8 was puriﬁ  ed and used to 
transform Escherichia coli DH10Bac-competent cells (In-
vitrogen), which produced recombinant bacmids (baculovi-
rus shuttle vectors) containing the VP1 gene. Recombinant 
bacmids were then transfected into Sf9 cells (Riken Cell 
Bank, Ibaraki, Japan), and recombinant baculoviruses were 
isolated. Recombinant baculoviruses were used to infect 
≈3 × 106 conﬂ  uent Tn5 cells (Invitrogen) at a multiplicity of 
infection of 5–10 in 1.5 mL of Ex-Cell 405 medium (JRH 
Biosciences, Lenexa, KS, USA), and the infected cells 
were incubated at 26°C. The culture medium was harvested 
5–6 d postinfection, centrifuged for 10 min at 3,000× g, 
and further centrifuged for 30 min at 10,000× g. VLPs were 
concentrated by ultracentrifugation for 2 h at 45,000 rpm at 
4°C (Beckman TLA-55 rotor; Beckman Coulter, Fullerton, 
CA, USA), and resuspended in 30 μL of Grace’s medium. 
Samples were examined for VLP formation by electron mi-
croscopy as described (10), and large-scale production of 
VLPs was performed as described (24).
Antibody Production
Hyperimmune sera to newly expressed VLPs of SaV 
(Syd53 and Syd3) were prepared in rabbits and guinea pigs. 
The ﬁ  rst subcutaneous injection was performed with puri-
ﬁ  ed VLPs (≈10 μg) in Freund complete adjuvant. After 3 
weeks, the animals received 1 booster injection (intrave-
nously in rabbits and subcutaneously in guinea pigs) of 10 
μg of VLPs without adjuvant. Blood was collected from the 
animals 1 week after their last booster injection.
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Antibody ELISA
Cross-reactivities among antiserum samples against 
SaV were examined by using an antibody ELISA with hy-
perimmune rabbit antibodies against VLPs. Brieﬂ  y, wells 
of 96-well microtiter plates (Maxisorp; Nunc, Roskilde, 
Denmark) were each coated with 100 μL of puriﬁ  ed VLPs 
(≈1.0  μg/ mL in carbonate-bicarbonate buffer, pH 9.6) 
(Sigma, St. Louis, MO, USA) and incubated overnight at 
4°C. Wells were washed twice with phosphate-buffered 
saline (PBS) containing 0.1% Tween 20 (PBS-T) and 
blocked with PBS containing 5% skim milk (PBS-SM) for 
1 h at room temperature. Wells were then washed 4 times 
with PBS-T, 100 μL of 2-fold–diluted hyperimmune rabbit 
antibodies from an initial concentration of 1:500 in PBS-
T-SM was added to each well, and the plates were incu-
bated for 1 h at 37°C. Wells were then washed 4 times with 
PBS-T, and 100 μL of a 1:1,000 dilution of horseradish 
peroxidase–conjugated goat antirabbit immunoglobulin G 
diluted in PBS-T-SM was added to each well. Plates were 
incubated for 1 h at 37°C. Wells were then washed 4 times 
with PBS-T, and 100 μL of substrate (o-phenylenediamine) 
and H2O2 were added to each well, and the plates were left 
in the dark for 30 min at room temperature. The reaction 
was stopped by the addition of 50 μL of 2N H2SO4 to each 
well, and the absorbance was measured at 492 nm (A492). 
The optical density (OD) cutoff point was determined to be 
0.15, which was equal to 3 times the mean OD of preim-
mune serum (5).
Antigen ELISA
Cross-reactivities among VLPs were also examined by 
using an antigen ELISA. Brieﬂ  y, wells were coated with 
100 μL of a 1:8,000 dilution of hyperimmune rabbit antise-
rum diluted in PBS (except for Syd3, for which a 1:3,000 
dilution was used), and the plates were incubated overnight 
at 4°C. Wells were washed 4 times with PBS-T and blocked 
with PBS-SM for 1 h at room temperature. Wells were then 
washed 4 times with PBS-T, 100 μL of VLPs (≈1.0 μg/mL 
in carbonate-bicarbonate buffer, pH 9.6) (Sigma) was add-
ed to duplicate hyperimmune rabbit wells, and the plates 
were incubated for 1 h at 37°C. Wells were then washed 
4 times with PBS-T, 100 μL of a 1:8,000 dilution of hy-
perimmune guinea pig antibody diluted in PBS-T-SM was 
added to each well (except for Syd3, which used a 1:3,000 
dilution), and the plates were incubated for 1 h at 37°C. 
Wells were washed 4 times with PBS-T, and 100 μL of a 
1:1,000 dilution of horseradish peroxidase–conjugated rab-
bit antiguinea pig immunoglobulin G diluted in PBS-T-SM 
was added to each well. The plates were then processed 
as described above. On the basis of our previous study, a 
specimen with an A492 (P – N) >0.1 and a P/N ratio >1.34 
(where P is hyperimmune antiserum and N is preimmune 
antiserum) was considered signiﬁ  cantly positive (4).
Results
Sequence Analysis
The sequence of the 3′ end of the genome (≈2,600 nt), 
i.e., VP1 to poly(A), for the newly expressed SaV strains 
(Syd53 and Syd3) was determined. Genetic analysis was 
performed with only complete VP1 sequences, which in-
cluded sequences from our epidemiologic studies and other 
sequences available on the database (Figure 1). Five SaV 
GI and 6 GII genotypes were observed, but only 1 genotype 
for SaV GIV and 1 for GV was found. This result suggests 
that SaV GI and GII strains were more genetically diverse, 
prevalent, or more virulent than SaV GIV and GV strains. 
However, because the SaV GIV and GV strains were only 
recently detected (26,27), this result may reﬂ  ect only the 
speciﬁ  city and sensitivity of the detection methods used. 
On the basis of our previous classiﬁ  cations, SaV Mc114 
and Yokote1 sequences both belonged to GI, but to dif-
ferent genotypes, GI/1 and GI/5, respectively; Syd53 be-
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Figure 1. Phylogenetic tree of sapoviruses on the basis of entire 
nucleotide sequences of the capsid protein. Different genogroups 
and genotypes are indicated. The numbers on each branch indicate 
the bootstrap values for the genotype. The scale bar at the lower left 
represents nucleotide substitutions per site. GenBank accession 
nos. for reference strains: Arg39, AY289803; Bristol, HCA249939; 
C12, AY603425; Chiba000496, AJ412800; Chiba010658, 
AJ606696; Cruise ship, AY289804; Dresden, AY694184; Ehime643, 
DQ366345; Ehime1107, DQ058829; Houston27, U95644; 
Manchester, X86560; Mc2, AY237419; Mc10, AY237420; Mc114, 
AY237422; Mex340, AF435812; NK24, AY646856; Parkville, 
U73124; PEC, AF182760; Potsdam, AF294739; Sapporo, U65427; 
SK15, AY646855; Stockholm, AF194182; SW278, DQ125333; 
Syd3, DQ104357; Syd53, DQ104360; and Yokote1, AB253740. RESEARCH
longed to GII/3; Syd3 belonged to GIV/1; and NK24 be-
longed to GV/1. SaV GI/1 Mc114 and GI/5 Yokote1 VP1 
sequences shared 76.5% and 79% nucleotide similarity and 
amino acid identity, respectively (Table 1). The nucleotide 
similarity and amino acid identity among the genogroups 
was low, i.e., <60% (Table 1).
Expression of VP1
We previously expressed SaV GI/1 Mc114, GI/5 Yo-
kote1, and GV/1 NK24 in insect cells, which resulted in the 
formation of VLPs morphologically similar to native SaV 
(5,10). In this study, we newly expressed SaV GII/3 Syd53 
and GIV/1 Syd3 in insect cells to analyze the cross-reactiv-
ity among all human SaV genogroups. SaV GII/3 Syd53 
and GIV/1 Syd3 successfully formed VLPs with a diameter 
of 41 to 46 nm and were morphologically similar to native 
SaV (Figure 2). Hyperimmune sera against these puriﬁ  ed 
VLPs were prepared in rabbits and guinea pigs.
Antibody ELISA Analysis
Our previous antibody ELISA result showed that SaV 
GI/1 Mc114 and GV/1 NK24 antisera had no cross-reac-
tivities against heterologous GV/1 NK24 and GI/1 Mc114 
VLPs, respectively (5). In the current study, cross-reactivi-
ties among 5 VLPs of SaV (GI/1 Mc114, GI/5 Yokote1, 
GII/3 Syd53, GIV/1 Syd3, and GV/1 NK24) were analyzed 
by using the antibody ELISA with 2-fold serial dilutions 
(1:500–1:1,024,000) of hyperimmune antiserum (Figure 
3). The OD cutoff point was 0.15, which was equal to 3 
times the mean OD of preimmune serum (5). Hyperimmune 
rabbit antiserum reacted strongly against the homologous 
VLPs (Table 2, Figure 3). SaV GII/3 Syd53 and GIV/1 
Syd3 antisera titers were 512,000 and 2,056,000, respec-
tively (Table 2). Several antisera weakly cross-reacted with 
heterologous VLPs. SaV GI/1 Mc114 antiserum cross-re-
acted weakly with GI/5 Yokote1 and GII/3 Syd53 VLPs, 
i.e., their cross-reactivities were 8- and 16-fold lower than 
that of the homologous VLP titer, respectively. SaV GI/5 
Yokote1 antiserum cross-reacted weakly with GI/1 Mc114 
and GII/3 Syd53 VLPs, i.e., its cross-reactivity was 16-fold 
lower than that of the homologous VLP titer. SaV GII/3 
Syd53, GIV/1 Syd3, and GV/1 NK24 antisera appeared to 
have no cross-reactivities against any of the heterologous 
VLPs, i.e., their cross-reactivities were >32-fold lower than 
those of the homologous VLP titer. These results suggested 
that SaV GI/1 Mc114 and GI/5 Yokote1 antiserum had 
weak 2-way cross-reactivities against GI/5 Yokote1 and 
GI/1 Mc114 VLPs, respectively. The negative control NoV 
Osaka659 antiserum showed no cross-reactivities against 
VLPs of SaV at any dilution of antiserum, which indicates 
that the antiserum was speciﬁ  c for the VLPs and not the 
insect cell proteins.
Antigen ELISA Analysis
On the basis of a previous study, a specimen with an 
A492 (P – N) >0.10 and a P/N ratio >1.34 was considered 
signiﬁ  cantly positive (4). Our recent antigen ELISA re-
sults showed that SaV GI Mc114, GI/5 Yokote1, and GV/1 
NK24 VLPs were antigenically distinct (19), i.e., GI/1 
Mc114 P– N 0.41, P/N 9.19; GI/5 Yokote1 P – N  0.93, 
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Table 1. Nucleotide similarity (values below blank diagonal) and amino acid identity (values above blank diagonal) of complete capsid
(VP1) sequences of sapovirus strains* 
Strain Mc114 (GI/1)  Yokote1 (GI/5)  Syd53 (GII/3)  Syd3 (GIV/1)  NK24 (GV/1) 
Mc114 (GI/1) 79 46 52 51
Yokote1 (GI/5)  76.5 46.8 50.3 50.9
Syd53 (GII/3)  56.1 56.9 48.3 48.6
Syd3 (GIV/1)  58.1 57.4 55.9 54.2
NK24 (GV/1) 58.2 57.3 56.4 58.6
*Values are percentages. 
Figure 2. Electron micrographs of A) 
Syd53 and B) Syd3 viruslike particles 
of sapovirus. Scale bars = 100 nm.Antigenic Diversity of Human Sapoviruses
P/N 19.59; and GV/1 NK24 P – N 1.03, P/N 21.58. In the 
current study, we examined the cross-reactivity among the 
newly expressed VLPs and those previously prepared by 
using the antigen ELISA. The antiserum samples reacted 
only with homologous VLPs, i.e., SaV GII/3 Syd53 P – N 
1.02, P/N 21.33; and GIV/1 Syd3 P – N 1.44, P/N 29.74 
(Table 3). Several antisera appeared to cross-react with het-
erologous VLPs, i.e., where the P – N was <0.10, but the 
P/N ratio was >1.34. SaV GI/5 Yokote1 antisera appeared 
to cross-react with GII/3 Syd53 VLPs (P/N 1.97); GIV/1 
Syd3 antisera appeared to cross-react with GI/5 Yokote1 
VLPs (P/N 1.42); and GV/1 NK24 antisera appeared to 
cross-react with GII/3 Syd53 VLPs (P/N 1.50). However, 
all of these cross-reactivity results were considered nega-
tive because P – N was <0.10.
Amino Acid Alignment and Secondary 
Structure Prediction
An amino acid alignment of the 5 SaV VP1 sequences 
(GI/1 Mc114, GI/5 Yokote1, GII/3 Syd53, GIV Syd3, and 
GV NK24) showed that the shell domain contained more 
conserved residues than the predicted P domains (Figure 
4). However, SaV GI/1 Mc114 and GI/5 Yokote1 shared 
more conserved continuous residues in the predicted P2 
subdomain than other genogroups. The NoV P2 subdomain 
is thought to contain the determinants of strain speciﬁ  c-
ity, cell binding, and antigenicity. For example, monoclo-
nal antibodies that recognize regions in the P2 subdomain 
inhibit binding of NoV VLPs to cells (28,29). In a recent 
study, we analyzed cross-reactivities among 26 different 
NoV VLPs (6 GI and 12 GII genotypes) (30) and found 
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Figure 3. Antibody ELISA absorbances at 492 nm of 6 viruslike particles (VLPs) of sapovirus. A) Mc114 GI/1; B) Yokote1 GI/5; C) Syd53 
GII/3; D) Syd3 GIV/1; E) NK24 GV/1; F) NoV Osaka659. Wells were coated with ≈100 ng of puriﬁ  ed VLPs. Antiserum was used in 2-fold 
dilutions from 1:500 to 1,024,000 in phosphate-buffered saline, 0.1% Tween 20, 5% skim milk shown as 1–12 along the x-axis. OD, optical 
density; NoV, Norwalk virus.
Table 2. Titers of antisera to viruslike particles of sapovirus strains in an antibody ELISA 
Antisera Mc114 (GI/1)  Yokote1 (GI/5) Syd53 (GII/3)  Syd3 (GIV/1)  NK24 (GV/1) 
Mc114 (GI/1)  512,000 64,000 32,000 1,000 <1,000
Yokote1 (GI/5)  32,000 512,000 32,000 2,000 4,000
Syd53 (GII/3)  4,000 8,000 512,000 4,000 <1,000
Syd3 (GIV/1)  2,000 16,000 8,000 2,056,000 1,000
NK24 (GV/1) 2,000 2,000 4,000 1,000 2,056,000RESEARCH
broad-range cross-reactivities for several NoV antisera. 
Our results suggested that these cross-reactivities were due 
to conserved amino acid residues located outside the P2 do-
main. Conversely, secondary structure predictions made by 
using PSIPRED secondary structural prediction software 
showed that helix structures could also inﬂ  uence the cross-
reactivity among the NoV VLPs. In the current study, we 
determined the secondary structure of the 5 SaV VP1 ami-
no acid sequences. Overall, SaV VP1 structures appear to 
be similar (online Appendix Figure, available from www.
cdc.gov/EID/content/13/10/1519-appG.htm). The location 
of 3 helix structures in the shell domain and 1 helix struc-
ture in the C-terminal region were nearly identical for the 5 
SaV VP1 sequences. Only SaV GV/1 NK24 was predicted 
to have a single helix structure in the P2 subdomain. These 
results suggested that the amino acid sequence, particularly 
the P2 subdomain, plays a major role in determining cross-
reactivity among SaV strains. However, additional stud-
ies, including high-resolution VLP structural analysis, are 
needed.
Discussion
In this study, we analyzed genetic and antigenic rela-
tionships for 4 human SaV genogroups (GI, GII, GIV, and 
GV). We observed weak 2-way cross-reactivity with SaV 
GI/1 Mc114 and GI/5 Yokote1 antisera against the heterol-
ogous GI/5 Yokote1 and GI/1 Mc114 VLPs, respectively, 
by using an antibody ELISA. However, when we used an 
antigen ELISA, we found that GI/1 Mc114 and GI/5 Yo-
kote1 VLPs were antigenically distinct. These weak cross-
reactivities identiﬁ  ed by using the antibody ELISA may 
have been inﬂ  uenced by several factors, including unfolded 
VLPs on the microtiter plates at the high pH (carbonate-
bicarbonate buffer, pH 9.6) (31) or conserved continuous 
residues outside the predicted P2 domain. Therefore, these 
2 SaV genotypes (GI/1 and GI/5) are for the most part an-
tigenically distinct. Likewise, we found that the 4 human 
SaV genogroups were antigenically distinct in the antigen 
ELISA. To our knowledge, these new ﬁ  ndings provide the 
ﬁ  rst evidence that SaV antigenicity corresponded well with 
VP1 genogrouping and genotyping.
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Table 3. Antigen ELISA absorbance values of viruslike particles of sapovirus strains 
Viruslike particles, P – N (P/N)* 
Antisera Mc114 (GI/1)  Yokote1 (GI/5)  Syd53 (GII/3)  Syd3 (GIV/1)  NK24 (GV/1) 
Mc114 (GI/1)  0.41 (9.19)  0 (1.00)  0 (1.00)  0 (1.00)  0 (1.00) 
Yokote1 (GI/5)  0.01 (1.13)  0.93 (19.59)  0.05 (1.97)  0 (1.00)  0 (1.00) 
Syd53 (GII/3)  0 (1.00)  0.02 (1.42)  1.02 (21.33)  0.01 (1.14)  0.03 (1.50) 
Syd3 (GIV/1)  0 (1.00)  0 (1.00)  0 (1.00)  1.44 (29.74)  0 (1.00) 
NK24 (GV/1)  0 (1.00)  0 (1.00)  0 (1.00)  0.01 (1.11)  1.03 (21.58) 
*Measured at 492 nm. P, hyperimmune serum; N, preimmune serum. 
Figure 4. Amino acid alignment of capsid (VP1) 
sequences of sapoviruses GI/1 Mc114, GI/5 
Yokote1, GII/3 Syd53, GIV/1 Syd3, and GV/1 
NK24. Sequences in rectangular boxes represent 
predicted P2 domains (13). Asterisks indicate 
conserved amino acids among these 3 VP1 
sequences.Antigenic Diversity of Human Sapoviruses
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